







# ROBUST PIPELINE OF SWITCH-CONTROL KINASE INHIBITORS

		PRE-CLINICAL	PHASE 1	PHASE 1/2	PHASE 3	REGULATORY SUBMISSION	APPROVED	COMMERCIAL RIGHTS	
<b>QINLOCK</b> (ripretinib) 50mg tablets Broad-Spectrum Inhibitor of KIT and PDGFRA	GIST ≥4 <sup>th</sup> Line (INVICTUS Study)						 + Global Approvals <sup>2</sup>		 <sup>1</sup>
<b>Vimseltinib</b> Selective Inhibitor of CSF1R	TGCT (Phase 3 MOTION Study)								
	TGCT (Phase 1/2 Study)								
<b>DCC-3116</b> Selective Inhibitor of ULK	RAS/MAPK Mutant Cancers In Combination with Trametinib, Binimetinib <sup>4</sup> , or Sotorasib <sup>4</sup>								
<b>Pan-RAF Program</b> Inhibitor of RAF Kinases	Solid Tumors								
<b>VPS34 Program</b> Selective Inhibitor of VPS34	Solid Tumors							 <sup>3</sup>	



**Notes:** CSF1R=colony-stimulating factor 1 receptor; GIST=gastrointestinal stromal tumor; KIT=KIT proto-oncogene receptor tyrosine kinase; MAPK=mitogen-activated protein kinase; PDGFRA=platelet-derived growth factor receptor  $\alpha$ ; RAF=rapidly accelerated fibrosarcoma; RAS=rat sarcoma gene; TGCT=tenosynovial giant cell tumor; ULK=unc-51-like autophagy-activating kinase; (1) Exclusive development and commercialization license with Zai Lab in Greater China for QINLOCK; (2) QINLOCK is approved for 4th line GIST in the United States, Australia, Canada, China, European Union, Hong Kong, Switzerland, Taiwan, and the United Kingdom; (3) Agreement with Sprint Bioscience for exclusive in-license worldwide rights to a research-stage program targeting VPS34; (4) subject to feedback from regulatory authorities.